NCT06338995

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 510 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.

Conditions

• Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Interventions

Type	Name	Description
DRUG	LY3650150	Administered SC.
DRUG	Placebo	Administered SC.
DRUG	Standard therapy for INCS	Administered as intranasal spray.

Timeline

• Start date: 2024-04-29
• Primary completion: 2027-05-01
• Completion: 2028-03-01
• First posted: 2024-04-01
• Last updated: 2026-03-24

Locations

190 sites across 19 countries: United States, Argentina, Belgium, Bulgaria, Canada, China, Denmark, Germany, Hungary, Italy, Japan, Mexico, Poland, Portugal, Romania, South Korea, Spain, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study